News Quantified

ALPMY – astellas pharma unsp/adr (US:NASDAQ)

Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting [Yahoo! Finance]

12/5

08:00 am

alpmy

Low

Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting

Astellas Pharma (TSE:4503): Exploring Valuation After Strong 21% Monthly Share Price Rally [Yahoo! Finance]

Lung Transplant Rejection Research Report 2025-2035: TFF Pharmaceuticals and Astellas Lead by Investing Heavily in R&D to Improve Existing Immunosuppressive Therapies, and Develop New Biologics [Yahoo! Finance]

Astellas Pharma (OTCMKTS:ALPMY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}